BLBharati Limbu

Bharati Limbu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bharati Limbu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Australian Psychotropic Medicines Training Program for Disability Support Workers: A Study Protocol in Easy Read

    by Michelle Bellon, Tim Cahalan, Shoumitro Deb, Kathryn Speer, Mary Bushell, Bharati Limbu, Andrea Simpson, Rebecca Koncz, Macey Barratt

    Objectives: This study aims to develop and evaluate an Australian training program for disability support workers about psychotropic medicines, with a focus on supporting people with intellectual disability in safe and person-centred ways. Methods: A co-design approach will be utilised, underscored by a participatory action framework. The training program developed will follow Universal Design for Learning and person-centred focuses. Co-design will include people with intellectual disabilities, family members, members of the disability workforce, healthcare professionals, and educational designers. Conclusions: The development of the training program will include a learning needs analysis, rapid review, the development of a consumer advisory committee, expert panel group, focus groups, co-design events, pilot testing, feasibility testing, implementation of the training program, and evaluation of the training program. This training program will aim to improve the knowledge and confidence of psychotropic medicines for disability support workers, provide education on supportive decision-making, and reduce inappropriate use of psychotropic medicines.


  • Open Access

    A network meta-analysis of randomised controlled trials of antipsychotic medications to assess their comparative efficacy and tolerability in autistic people

    by Shoumitro Deb, Bharati Limbu, Jose Antonio Lopez Lopez, Meera Roy, Meena Murugan, Ashok Roy, Basma Akrout Brizard, Jacopo Santambrogio

    Background A high proportion of autistic people receive off-license antipsychotic medication, often in the absence of a mental illness, primarily for behaviours that challenge, which is a public health concern. Although meta-analyses have been published recently, there is a lack of a comprehensive network meta-analysis to inform clinicians about the relative efficacy and safety of antipsychotic medications. Aims To conduct a network meta-analysis of available RCTs of antipsychotic medications involving autistic participants to assess the relative efficacy of different antipsychotics and their adverse effects. Method We searched seven databases and hand-searched ten relevant journals. Two authors independently screened titles, abstracts, and full papers, extracted data, and assessed their quality. Results We analysed data from 22 RCTs involving 1562 autistic people. The largest mean difference with 95% confidence interval in the Aberrant Behaviour Checklist-Irritability (ABC-I) score compared with placebo was from the combined intervention with risperidone and parent training: -11.16 (-15.13, -7.18), followed by risperidone: -7.59 (-9.22, -5.95), and aripiprazole: -5.59 (−7.18, −4). The largest effect on Clinical Global Impression-Improvement (CGI-I) scores was from risperidone, 7.65 (2.17, 27.04), followed by aripiprazole, 7.02 (1.92, 25.72), compared with placebo. Risperidone (4; 1.57, 10.21) and aripiprazole (2.77; 1.20, 6.39) had significantly higher odds ratios for adverse effects, but aripiprazole showed the least weight gain. Conclusions Combined parent training and risperidone followed by risperidone and aripiprazole showed the best effects on the ABC-I score, whereas risperidone and aripiprazole showed the greatest effect on the CGI-I score. However, risperidone and aripiprazole showed significantly increased adverse effects.

  • Open Access

    Process evaluation of SPECTROM training: Staff views from a feasibility cluster RCT

    by Bharati Limbu, Shoumitro Deb, Cecilia Vindrola-Padros

    Psychotropic medications, particularly antipsychotics, are commonly prescribed to people with intellectual disabilities for behaviours that challenge (Deb, 2024). Psychotropic medications are often...

  • Open Access

    ASPIRE-Med project: a study protocol on an Australian psychotropic medicines training programme for disability support workers

    by Macey Barratt, Kathryn Speer, Shoumitro Deb, Michelle Bellon, Timothy Cahalan, Andrea Simpson, Rebecca Koncz, Bharati Limbu, Mary Bushell

    Introduction Overmedication of off-label use of psychotropic medicines to address behaviours of concern in people with intellectual and developmental disabilities is a major public health concern. Disability support workers (DSWs) play a pivotal role in supporting adults with intellectual and developmental disabilities who are prescribed psychotropic medicines. Therefore, there is an urgent need to train DSWs to help understand the appropriate use of these medicines. This paper describes the protocol of a project that aims to develop such a programme. Methods and analysis A participatory action framework will underscore the programme and follow a Universal Design for Learning approach. It will be a co-production involving all stakeholders, including people with intellectual and developmental disabilities, their families, members of the disability workforce, healthcare professionals and educational designers. The programme will be developed using the following steps: (a) development of a consumer advisory committee and expert panel groups, (b) an online survey of learning needs analysis, (c) a rapid umbrella review of the relevant literature, (d) focus groups involving participants from different parts of Australia, (e) co-design events in four Australian cities, (f) field testing on 6–12 DSWs to determine any practical difficulties of implementing the programme, (g) a feasibility trial involving at least 1200 DSWs using a train-the-trainer model and online resources and (h) a mixed-method process evaluation using interviews of a purposive sample of trainees and online questionnaire survey. Ethics and dissemination Ethics approval will be sought at each stage of the co-design process. Each step of the project will include an academic language paper and Easy Read report developed. The training programme will be shared across Australia, with DSWs able to complete the project for free. We expect the training will help improve DSWs’ knowledge of appropriate psychotropic medicine prescribing in people with intellectual and developmental disabilities, confidence in effectively communicating with health professionals and using non-pharmacological approaches to support behaviours of concern, promote shared decision-making with clients, advocate for psychotropic medicine reviews by healthcare professionals, encourage positive interactions with people with intellectual and developmental disabilities and their families and self-reflection on their own behaviour and attitude can influence their client and behaviours of concern.

  • Open Access

    A whole population-based cohort study of the trajectory of the prevalence and the incidence of mental illness, challenging behaviour, and psychotropic medication prescribing in adults with intellectual disabilities in the Czech Republic between 2010 and 2022

    by Shoumitro Deb, Jiří Jarkovský, Hana Melicharová, David Holub, Bharati Limbu, Petr TřEšňák

    Background: It is essential to understand the complex interaction among mental illness, challenging behaviour and psychotropic medication prescribing among adults with intellectual disabilities to help reduce overmedication of psychotropics. Methods: We analysed data from the Institute of Health Information and Statistics of the Czech Republic to estimate the prevalence of mental illness, challenging behaviour and psychotropic prescribing between 2010 and 2022 and incidence between 2015 and 2022. Results: 62,636 (54% males) adults with intellectual disabilities contributed 704,503 person-years of data. In 2010, the prevalence of concomitant mental illness (ICD-10, F20-48) was 15·7%, challenging behaviour 29% and any psychotropic prescription 55%, increasing in 2022 to 17·3%, 30·5% and 59%, respectively. The prevalence of most individual mental illness categories either remained the same or marginally increased between 2010 and 2022, except anxiety disorders, the neurodevelopmental disorders like autism and attention-deficit hyperactivity disorder (ADHD), which showed a significant increase. The incidence of new diagnoses of mental illnesses and challenging behaviour decreased between 2015 and 2022, except for the neurodevelopmental disorders, which increased significantly. The incidence of challenging behaviour correlated significantly with psychoses, bipolar disorder, and anxiety disorder. The overall prevalence of most psychotropic prescribing correlated significantly with the prevalence of mental illnesses and challenging behaviour. Among those receiving antipsychotics, only 18% in 2010 and 19% in 2022 had severe mental illness (psychoses and/or bipolar disorder), which are the licensed indications for long-term antipsychotic prescriptions. In 2010, among those with challenging behaviour, 82% received psychotropics, 62% antipsychotics, 20% antidepressants, 17% anxiolytics, 30% mood stabilisers, and 0·4% hypnotics and sedatives. The incidence rates of new prescriptions among participants who displayed challenging behaviour fell for any psychotropics, antipsychotics, antidepressants and anxiolytics. However, the incidence of new prescriptions increased for mood stabilisers, and significantly for hypnotics/sedatives (Incidence Rate Ratio: 0.61; 95% Confidence Interval: 0.45–0.81; p < 0.001). Conclusions: Challenging behaviour was significantly associated with some mental illnesses. Both mental illness and challenging behaviour were significantly associated with psychotropic medication prescribing. The prevalence of psychotropic medication prescribing overall and especially among those displaying challenging behaviour was high and showed a significant increase in antidepressants and hypnotics/sedatives prescriptions over 12 years. Clinical trial number: Not applicable.


  • Open Access

    The Effect of SPECTROM Training on Support Staff Knowledge of Psychotropic Medicine and Attitude Towards Behaviours That Challenge in Adults With Intellectual Disabilities to Help Implement the STOMP Initiative

    by B. Limbu, S. Deb, J. Bradshaw, V. Cooper

    Background: Overmedication of adults with intellectual (learning) disabilities, particularly the off‐licence use of psychotropic medicines for behaviours that challenge in the absence of a psychiatric disorder, is a major public health concern and an example of health inequalities. In the United Kingdom, we coproduced online training resources backed up by face‐to‐face training for support staff (direct care workers) called SPECTROM involving all stakeholders, including adults with intellectual disabilities and their families, to help reduce the overmedication and implement NHS England's STOMP initiative.Method: In a feasibility cluster randomised controlled trial, we trained service managers and support staff using two core modules of SPECTROM, namely, (a) Medicine/STOMP and (b) Alternatives to Medicine (ATM) using an online platform. These two core modules introduced 12 other modules and other online resources. We assessed trainees' knowledge of psychotropic medicines using the Psychotropic Knowledge Questionnaire‐Revised (PKQ‐R) and their attitude to behaviours that challenge using the Management of Aggression and Violence Attitude Scale‐Revised‐Intellectual Disabilities (MAVAS‐R‐ID) using a pre–post training design.Results: The research team delivered SPECTROM training to 18 service managers and 122 support staff. Of the 140 trainees, 126 completed PKQ‐R at baseline before and within 4 weeks after the training. There was a post‐training improvement in PKQ‐R scores in 42 of the 43 questions (97.7%), 22 of which were statistically significant differences (p < 0.001). The MAVAS‐R‐ID was completed at baseline and within 4 weeks of training by 125 trainees. The MAVAS‐R‐ID total score showed statistically significant post‐training improvements (p < 0.01). Individual domain score analysis showed a statistically significant improvement in one of the five domains related to attitude regarding the use of medicine for behaviours that challenge.Conclusions: The SPECTROM training seems to improve staff knowledge of psychotropic medicine, at least in the short‐term, and attitude towards behaviours that challenge, particularly concerning the use of psychotropic medicine.


  • Open Access

    A whole population-based cohort study of the trajectory of the prevalence and the incidence of mental illness, challenging behaviour, and psychotropic medication prescribing in adults with intellectual disabilities in the Czech Republic between 2010 and 2022

    by S Deb, J Jarkovský, H Melicharová, D Holub, B Limbu, P Třešňák

    Background: It is essential to understand using a sizeable, centralised health database, the complex relationship among mental illness, challenging behaviour and psychotropic medication prescribing to help reduce the inappropriate overmedication of adults with intellectual disabilities. Diagnosing mental illness in adults with intellectual disabilities could be difficult because of the communication challenges and sometimes atypical manifestation, for example, through challenging behaviour. Method: We explored the change in prevalence between 2010 and 2022 and incidence of mental illness, challenging behaviour and psychotropic medication prescribing between 2015 and 2022 among adults with intellectual disabilities and the relationships among them using a national health register in the Czech Republic. We collected data from the Institute of Health Information and Statistics of the Czech Republic. Results: 62,636 (54% males) adults with intellectual disabilities contributed 704,503 person-years of data. In 2010, the prevalence of overall mental illness was 15·7%, challenging behaviour 29% and any psychotropic prescription 55%, increasing significantly by 2022 to 17·3%, 30·5% and 59%, respectively. The prevalence of overall mental illness, anxiety disorder, autism, ADHD and challenging behaviour increased significantly between 2010 and 2022. On the other hand, the incidence of newly diagnosed cases of most mental illnesses and challenging behaviour decreased significantly between 2015 and 2022. In contrast, the incidence of autism, ADHD, sleep disorders, and dementia increased significantly between 2015 and 2022. The incidence of challenging behaviour correlated significantly with psychoses, bipolar, anxiety and personality disorders. The prevalence of most psychotropic prescriptions increased significantly from 35% for antipsychotics, 17% for antidepressants, and 23% for mood stabilisers in 2010 to 37% for antipsychotics, 25% for antidepressants, and 28% for mood stabilisers in 2022 apart from anxiolytics which decreased from 14% in 2010 to 13% in 2022, despite a drop in the incidence of new prescriptions. The rate of psychotropic prescribing correlated significantly with the rate of mental illness and challenging behaviour. Among those receiving antipsychotics, only 18% in 2010 and 19% in 2022 had severe mental illness for which antipsychotics are indicated. Therefore, in >80% of cases, antipsychotic medications were prescribed off-label primarily for challenging behaviour. Similar trends were observed for other psychotropics. For example, mood stabilisers and antidepressants were prescribed more often for challenging behaviour in 38%-40% and 33%-40% of cases, respectively, than bipolar disorder (1%) and depression (8%-11%), respectively. In 2010, among those with challenging behaviour, 82% were prescribed any psychotropic medications, 62% antipsychotics, 20% antidepressants, and 30% mood stabilisers, increasing significantly by 2022 to 87%, 63%, 33%, and 37%, respectively. However, the prevalence of anxiolytic prescribing decreased significantly from 17% in 2010 to 14% in 2022. The incidence rates of new prescriptions for challenging behaviour fell by 1·1% for any psychotropic medications, 0·8% for antipsychotics, 0·7% for antidepressants and 0·1% for anxiolytics, but increased by 0·3% for hypnotics/sedatives and 0·4% for mood stabilisers. Conclusions: The prevalence of mental illness and challenging behaviour increased over 12 years despite a drop in their incidences. This may indicate the chronic nature of these conditions. Challenging behaviour was significantly associated with some mental illnesses. Both mental illness and challenging behaviour were significantly associated with psychotropic medication prescribing. The prevalence of all psychotropic medication prescribing overall and especially for challenging behaviour was high and increased significantly over 12 years. This probably indicates long-term use of these medications. Antipsychotic medications were prescribed for severe mental illness only in a minority of cases. This indicates an off-licence use of antipsychotic medications in a very high proportion of cases. This trend of off-licence use was also evident in other psychotropic medications than antipsychotics. On the contrary, these medications were primarily used for challenging behaviour. The incidence of new prescriptions of antipsychotics, antidepressants, and anxiolytics decreased over the years, possibly at the expense of increased new prescriptions of mood stabilisers, primarily antiepileptics and also hypnotics/sedatives. The reasons for the significant increase in already high psychotropic medication prescription over 12 years and the trend of increase in new prescriptions of mood stabilisers and hypnotics/sedatives require scrutiny.